US 10434075
FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
granted A61KA61K31/138A61K31/167
Quick answer
US patent 10434075 (FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer) held by The Board of Regents of the University of Texas System expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/138, A61K31/167, A61K31/17, A61K31/337